Abstract
PurposeThe use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the efficacy and safety of carfilzomib (CFZ) and pomalidomide (POM).ResultsBased on our research criteria, we identified 37 prospective studies that evaluated 1160 patients. Analysis of subgroup differences between carfilzomib single-agent and CFZ/DEX dual combination showed significantly(P < 0.001, I2 = 96.3%), suggesting the overall response rate (ORR) of 66% attained from CFZ/DEX dual combination seemed to be higher than that of 28% from carfilzomib single-agent. And, the same trend favoring CFZ/DEX dual combination was found in ≥VGPR and CBR analysis. The ORR of 31% attained from POM/DEX dual combination was superior to that of 19% from pomalidomide single-agent(P < 0.001, I2 = 94.4%). And, the same trend favoring POM/DEX dual combination was found in ≥VGPR and CBR analysis. However, the ORR of 83% attained from POM/BOR/DEX triplet combination was superior to that of 31% from POM/DEX dual combination(P < 0.001, I2 = 99.1%). And, the same trend favoring POM/BOR/DEX triplet combination was found in ≥VGPR analysis.MethodsWe searched published reports including carfilzomib and (or) pomalidomide therapy for RRMM who had received bortezomib and (or) lenalidomide.ConclusionPomalidomide/Carfilzomib plus dexamethasone seemed to attain a superior response rate compared with pomalidomide/carfilzomib single-agent. Furthermore, the combination of pomalidomide, bortezomib and dexamethasone resulted in a much higher response rate compared with pomalidomide plus dexamethasone regimen. These results needed more validation in future trials.
Highlights
In the past decades, the administration of novel agents had produced a pronounced shift in the treatment framework for myeloma patients
Based on our research criteria, we identified 37 prospective studies of carfilzomib and pomalidomide enrolling a total of 3432 patients with RRMM [13,14,15,16,17,18,19,20,21]
Analysis of subgroup differences between carfilzomib single-agent and CFZ/DEX dual combination showed significantly (P < 0.001, I2 = 96.3%), suggesting the overall response rate (ORR) of 66% attained from CFZ/DEX dual combination seems to be higher than that of 28% from carfilzomib single-agent
Summary
The administration of novel agents (thalidomide lenalidomide and bortezomib) had produced a pronounced shift in the treatment framework for myeloma patients. Treatment options and corresponding patient outcomes had greatly improved because of them. Myeloma still remained incurable, and most patients would relapse and resist these agents [1]. Relapsed disease was characterized by increasingly lower remission rate even following salvage therapy. Survival among those in whom www.impactjournals.com/oncotarget lenalidomide, bortezomib, and thalidomide have failed was especially poor [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
